US FDA grants fast track designation to NKGen Biotech’s natural killer cell therapy, troculeucel to treat moderate Alzheimer’s disease: Santa Ana, California Saturday, Februar ...
13h
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Hosted on MSN15h
EU reshapes HTAs: is the industry ready for it?New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.
A recent drug discovery could eventually help the visually impaired and those suffering from multiple sclerosis, traumatic stroke, and Alzheimer’s disease regain some of their vision and mental ...
Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback